Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Executive Summary

Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.

Advertisement

Related Content

Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Edging Toward Interchangeability in Biosimilars
Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared
Biosimilar Sponsors May Seek Interchangeability Before FDA Sets Rules

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel